Úvod Sample Clauses

Úvod. (i) INSTITUTION and INVESTIGATOR shall process Personal Data as determined in this Schedule III on behalf of ERGOMED (the Sponsor’s processor) as ERGOMED’s sub- processors. Nothing in this Agreement derogates or prevents the INSTITUTION or INVESTIGATOR to keep Clinical Trial and medical documentation as prescribed by the applicable mandatory Regulations, nor excludes their obligations and responsibilities as Controllers when they Process Personal Data of their employees, contractors, sub- contractors or Clinical Trial Subjects. (i) POSKYTOVATEL a ZKOUŠEJÍCÍ jsou povinni zpracovávat Osobní údaje podle této Přílohy č. III jménem společnosti ERGOMED (zpracovatel Zadavatele) jakožto dílčí zpracovatelé společnosti ERGOMED. Žádné ustanovení této Smlouvy nebrání nebo neomezuje POSKYTOVATELI nebo ZKOUŠEJÍCÍMU v plnění jejich povinnosti uchovávat dokumentaci Klinického hodnocení a zdravotnickou dokumentaci podle požadavků kogentních Předpisů, ani nevylučuje jejich povinnosti a odpovědnosti jakožto Správců při Zpracovávání Osobních údajů svých zaměstnanců, dodavatelů, subdodavatelů či Subjektů klinického hodnocení. (ii) INSTITUTION and INVESTIGATOR are responsible for compliance with their obligations as sub-processors in accordance with the Data Protection Laws. (ii) POSKYTOVATEL a ZKOUŠEJÍCÍ jakožto dílčí zpracovatelé nesou odpovědnost za plnění svých povinností v souladu se Zákony o ochraně osobních údajů. (iii) The technical and organizational measures regarding the security of the Personal Data Processing are specified in Schedule IV herein. (iii) Technická a organizační opatření k ochraně bezpečnosti Osobních údajů jsou uvedena v Příloze č. IV.
Sample 1Sample 2
AutoNDA by SimpleDocs
Úvod. XXXXX is a new standard and new solution of CUTE presented by IATA as a CUTE successor. IATA Common Use Recommended Practice (RP) 1797 has undergone significant changes to reflect new technology. A new version of RP 1797 has been published jointly by IATA, ATA, and ACI (IATA RP1797, ATA RP30.201, and ACI RP500A07). The RP is now called XXXXX – Common Use Passenger Processing Systems – with the same number, RP 1797. XXXXX je nový standard a nové řešení CUTE, jež IATA prezentuje jako nástupce CUTE. Doporučená praxe IATA Common Use Recommended Practice (RP) 1797 prošla významnými změnami tak, aby odrážela zavedení této nové technologie. Nová verze RP 1797 byla společně publikována IATA, ATA a ACI (IATA RP1797, ATA RP30.201, a ACI RP500A07). RP se nyní nazývá XXXXX – Common Use Passenger Processing Systems – a xxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx XX 0000. XXXXX is the next evolutionary step of Common- Use Terminal Equipment (CUTE), which addresses and corrects the majority of complains and deficiencies airlines perceived to be associated with the CUTE environment. XXXXX je dalším vývojovým krokem Common- Use Terminal Equipment (CUTE), který řeší a odstraňuje většinu stížností a nedostatků, které letecké společnosti vnímaly jako problém v prostředí CUTE. XXXXX is based on more open standards-based environment than CUTE and has been specifically designed to easily incorporate new technologies as they become available, as near field communications (NFC) devices. Technologie XXXXX je založena na více standardizovaném prostředí než CUTE a je určena především pro snazší začleňování nových technologií v době, kdy budou dostupné, jako jsou například zařízení s podporou near field communications (NFC). Additionally, XXXXX has well-defined technical standard, along with a third party certification processes, to ensure compatibility between different suppliers of XXXXX platforms and software. These additions address the major complains that airlines had with the CUTE environment. Technologie XXXXX má navíc dobře definovaný technický standard a také procesy pro certifikaci třetích stran, jimiž je zajištěna kompatibilita různých dodavatelů platforem a software XXXXX. Tyto dodatky řeší většinu výhrad leteckých společností, pokud jde o prostředí CUTE.
Sample 1
Úvod. The Breast International Group (BIG), Alliance Foundation Trials (AFT), Frontier Science and Technology Research Foundation (FS), Institut Xxxxx Xxxxxx (IJB) and Roche Products Limited (Roche) are conducting a clinical trial entitled “A phase III, multicentre, randomised, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer” (the “Study”), and this document outlines the Publication and Presentation Policy for this Study. Breast International Group (BIG), Alliance Foundation Trials (AFT), Frontier Science and Technology Research Foundation (FS), Institut Xxxxx Xxxxxx (IJB) a Roche Products Limited (Roche) provádějí klinické hodnocení s názvem „Multicentrická, randomizovaná, otevřená studie fáze III porovnávající atezolizumab (protilátku proti PD-L1) v kombinaci s adjuvantní chemoterapií založenou na antracyklinu/taxanu oproti chemoterapii samotné u pacientů s operabilním trojitě negativním nádorem prsu“(xxxx xxx „Studie“) a tento dokument uvádí přehled Zásad publikace a prezentace týkající se této Studie. The key principles outlined in this document are based on the publication guidelines of the lead partners in this Study (and BIG Guidelines for Publications and Presentations), and the International Committee of Medical Journal Editors (ICMJE) Uniform Requirements for Manuscripts submitted to Biomedical Journals, (xxx.XXXXX.xxx). Klíčové principy uvedené v tomto dokumentu jsou založeny na pokynech k publikaci vedoucích partnerů v této Studii (Pokyny BIG pro publikace a prezentace) a jednotných požadavcích komise International Committee of Medical Journal Editors (ICMJE) týkajících se rukopisů předložených biomedicínským časopisům (xxx.XXXXX.xxx).
Sample 1
Úvod. 1.1. This securities trading agreement (hereinafter the “Agreement”) is concluded between you, the client, and us, Admiral Markets Cyprus Ltd (Registration number HE310328, CySEC License number 201/13). We refer to ourselves as ‘AM CY’, ‘we’, ‘our’, ‘us’ and ‘ourselves’ as appropriate, and the client is referred to as ‘you’, ‘your’, ‘yours’, ‘yourself’ and ‘Client’ as appropriate. AM CY may choose to amend this Agreement as per clause 20, in accordance to its sole and absolute discretion. You do not have and shall not have any right whatsoever to amend this Agreement. 1.2. Through the “Invest.MT5” account, we provide services that relate to the placing of orders to purchase and sell securities, which securities include, but are not limited to, ETFs, listed units in limited liability partnerships and depositary receipts for shares of foreign companies. AM CY shall receive and accept orders from the Client for the specified physical securities that may be available from time to time to the type of client account for which the Client has been approved. AM CY is responsible for the receipt of orders by the Client. The Client understands that the Invest.MT5 account allows the purchase and sale of securities only. Once purchased, the securities in the Invest.MT5 account may only be transferred by way of sale. The Invest.MT5 account is a cash account and not a margined account. In the event that short selling becomes permitted, it may, at AM CY’s discretion on notice, become a margined account. You appoint AM CY as your agent for the purposes of providing the service to you in accordance with this Agreement. You acknowledge and agree that AM CY: a) may act as agent, in relation to the execution or arrange execution of orders and transactions on your behalf; b) will arrange for the safeguarding of any money you deposit in AM CY, in accordance to clause 8.2 of the Agreement. 1.3. In the event that a corporate action or capital event that includes issue in listed equity instruments that: a) are not outlined in clause 1.2; or b) are issued in jurisdictions not supported by AM CY; or c) are or will be traded in venues which AM CY cannot access; or d) are not available on AM CY’s trading platform for any other reason; AM CY nebude moci zahájit pravidelné obchodování s těmito nově vydanými nástroji a bude postupovat přiměřeně při realizaci těchto nástrojů na volném trhu a vypořádání s klientem v hotovosti podle vlastního uvážení AM CY. Vezměte prosím na vědomí, že tyto ...
Sample 1
Úvod. 1.1 Zadávateľ s radosťou víta, že Inštitúcia a Skúšajúci súhlasili s účasťou na klinickej výskumnej štúdii na báze spolupráce (ďalej ako „Štúdia“) v Inštitúcii opísanej ďalej, ktorú sponzoruje Zadávateľ. Ak má byť táto Štúdia prospešná všetkým stranám, je dôležité, aby zmluvné strany uzavreli dohodu s ohľadom na základné praktiky platné pre túto Štúdiu. V súlade s tým táto Dohoda uvádza termíny a podmienky platné pre toto výskumné úsilie na báze spolupráce. 1.2 Zadávateľ najal CRO, aby vykonával povinnosti a funkcie v mene a pre Zadávateľa v súvislosti so Štúdiou, vrátane, ale bez obmedzenia, monitorovania štúdie a manažmentu projektu v súlade s dohodou o zmluvných službách medzi Zadávateľom a CRO. 1.3 Zadávateľ podpísal Dohodu o obmedzenej pôsobnosti a splnomocnenie (ďalej ako „DOP“) pre CRO, aby mohol podpísať túto Dohodu v mene Zadávateľa v rámci rozsahu DOP. DOP je priložená k tejto Dohode ako Príloha č. 1.4 Právny zástupca zadávateľa v Európskej únii (EÚ) v zmysle čl. 19 Nariadenia EÚ 2001/20/EK, je FGK Representative Service GmbH, so sídlom na Xxxxxxxxxxxxxxx 00, 00000 Xxxxxxx, Nemecko. Kontaktná osoba je xxxx Xxxxxx Xxxxxx (e-mailová adresa xxxxxx.xxxxxx@xxx-xx.xx).
Sample 1

Related to Úvod

  • Exchange Agent Parent shall select a bank or trust company reasonably acceptable to Company to act as the exchange agent (the "EXCHANGE AGENT") in the Merger.

  • Distribution of Exchange Fund to Parent Any portion of the Exchange Fund that remains undistributed to the holders of the Certificates or Uncertificated Shares on the date that is one year after the Effective Time will be delivered to Parent upon demand, and any holders of shares of Company Common Stock that were issued and outstanding immediately prior to the Merger who have not theretofore surrendered or transferred their Certificates or Uncertificated Shares representing such shares of Company Common Stock for exchange pursuant to this Section 2.9 will thereafter look for payment of the Per Share Price payable in respect of the shares of Company Common Stock represented by such Certificates or Uncertificated Shares solely to Parent (subject to abandoned property, escheat or similar Laws), solely as general creditors thereof, for any claim to the Per Share Price to which such holders may be entitled pursuant to Section 2.7.

  • Sarnia-Lambton The full-time Nurse(s) assigned to a team will have first priority for RN work assignment within the team. Continuity of care for the patients shall be considered when determining patient assignments. The primary Nurse for a patient may be a full-time Nurse or a part-time Nurse. In all cases where there is work, which cannot be done by the full-time Nurse, the work shall be assigned to other Nurses in the following order:

  • Payment Fund “Payment Fund” is defined in Section 2.6(a) of the Agreement.

  • Pre-Layoff Canvass (a) Before a layoff occurs, the Employer may consult with the Union to discuss lessening disruption to clients and staff, as well as whether a pre-layoff canvass of employees is necessary or advisable and may be waived. If the pre-layoff canvass is not waived, then prior to the layoff of regular employees under Clause 13.3 (Layoff), the Employer will canvass employees in order to invite: (1) placement on the casual call-in and recall lists with no loss of seniority; or (2) early retirement; or (3) other voluntary options, as agreed to by the Union and the Employer. Where more than one employee expresses interest in one of the above options, they will be offered to qualified employees on the basis of seniority. (b) Responses from employees to the Pre-Layoff Canvass will only be received by the Employer for consideration if submitted within seven days of issuance of a written notice to the employee or group of employees. (c) Where an employee selects an option, once confirmed in writing by the employee and the Employer, such acceptance is final and binding upon the employee and the Employer. The Employer will notify the Union of the employee's selection.

  • Leave Time During the Employment Period, Employee shall be entitled to paid vacation and leave days each calendar year in accordance with the leave policies established by Employer from time to time. Any leave time not used during each fiscal year of Employer may be carried over into the next year to the extent permitted by Employer policy.

  • Exchange Fund Prior to the Effective Time, Parent or Merger Sub shall designate a bank or trust company reasonably acceptable to the Company to act as the exchange agent in connection with the Merger (the “Exchange Agent”). The Exchange Agent shall also act as the agent for the Company’s stockholders for the purpose of receiving and holding their Certificates and Book-Entry Shares and shall obtain no rights or interests in the shares represented thereby. At or immediately after the Effective Time, Parent or Merger Sub shall deposit, or cause to be deposited, with the Exchange Agent (i) evidence of Parent Stock issuable pursuant to Section 2.1(a) in book-entry form equal to the aggregate Parent Stock portion of the Merger Consideration (excluding any Fractional Share Consideration), and (ii) cash in immediately available funds in an amount sufficient to pay the aggregate cash portion of the Merger Consideration, Fractional Share Consideration, Option Consideration payable to holders who are not current or former employees of the Company or any Company Subsidiary (“Non-Employee Option Consideration”) and any dividends under Section 2.2(f) (such evidence of book-entry shares of Parent Stock and cash amounts, together with any dividends or other distributions with respect thereto, the “Exchange Fund”), in each case, for the sole benefit of the holders of shares of Company Common Stock and the persons entitled to receive the Non-Employee Option Consideration. In the event the Exchange Fund shall be insufficient to pay the aggregate Cash Consideration Portion, Fractional Share Consideration, Non-Employee Option Consideration and any dividends under Section 2.2(f), Parent shall, or shall cause Merger Sub to, promptly deposit additional funds with the Exchange Agent in an amount which is equal to the deficiency in the amount required to make such payment. Parent shall cause the Exchange Agent to make, and the Exchange Agent shall make, delivery of the Merger Consideration, including payment of the Fractional Share Consideration, Non-Employee Option Consideration and any amounts payable in respect of dividends or other distributions on shares of Parent Stock in accordance with

  • Uncertificated Shares Notwithstanding anything else herein, to the extent permitted under applicable foreign, federal, state or provincial law, the Committee may, issue the Shares in the form of uncertificated shares. Such uncertificated shares of Restricted Stock shall be credited to a book entry account maintained by the Company (or its designee) on behalf of the Participant. If thereafter certificates are issued with respect to the uncertificated shares of Restricted Stock, such issuance and delivery of certificates shall be in accordance with the applicable terms of this Agreement.

  • Termination of Exchange Fund Any portion of the Exchange Fund which remains undistributed to the holders of Company Common Stock for 180 days after the Effective Time shall be delivered to Parent, upon demand, and any holders of the Company Common Stock who have not theretofore complied with this Article II shall thereafter look only to Parent for the shares of Parent Common Stock, any cash in lieu of fractional shares of Parent Common Stock to which they are entitled pursuant to Section 2.02(e) and any dividends or other distributions with respect to the Parent Common Stock to which they are entitled pursuant to Section 2.02(c).

  • Unclaimed Property and Lost Shareholders The Transfer Agent shall report unclaimed property to each state in compliance with state law and shall comply with Section 17Ad-17 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for lost Shareholders. If the Fund is not in compliance with applicable state laws, there will be no charge for the first two years for this service for such Fund, other than a charge for due diligence notices (reflected on Schedule 5.1) provided that after the first two years, the Transfer Agent will charge such Fund its then standard fee plus any out-of-pocket expenses.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!